<SEC-DOCUMENT>0001818382-22-000037.txt : 20220513
<SEC-HEADER>0001818382-22-000037.hdr.sgml : 20220513
<ACCEPTANCE-DATETIME>20220513070335
ACCESSION NUMBER:		0001818382-22-000037
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220513
DATE AS OF CHANGE:		20220513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		22920209

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20220513.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:3b922dbf-dea4-4759-b5c2-38dd01002567,g:a24aa320-4436-4438-b9f7-72b0296329e1,d:1e89ae06699a417e87d4667667970318--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20220513</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF80L2ZyYWc6ZmE0Njk0OTg0OGQyNDgzYzhkMzBmOWVmYjBhYjIwYTgvdGFibGU6ZjdjODc3MDk1ZjdhNDAxMzhmZGQwNWJiZmJjYmE4NzYvdGFibGVyYW5nZTpmN2M4NzcwOTVmN2E0MDEzOGZkZDA1YmJmYmNiYTg3Nl8xLTEtMS0xLTM1MjM0_a56adc0c-46e9-45ab-ba2f-7235f7249cd1">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF80L2ZyYWc6ZmE0Njk0OTg0OGQyNDgzYzhkMzBmOWVmYjBhYjIwYTgvdGFibGU6ZjdjODc3MDk1ZjdhNDAxMzhmZGQwNWJiZmJjYmE4NzYvdGFibGVyYW5nZTpmN2M4NzcwOTVmN2E0MDEzOGZkZDA1YmJmYmNiYTg3Nl8yLTEtMS0xLTM1MjM0_2d2c3adf-ddff-471e-80ca-7d337d2598eb">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20220513.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-13</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-13</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-13</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1e89ae06699a417e87d4667667970318_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE5_44d2f2e5-d581-4207-a82a-6369bf73b831">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIw_4c30aa86-e978-4217-88ae-5839d6c0729f">May 13, 2022</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIx_77eb2a80-d35d-4625-b958-715baf3fc9cf"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIy_3c90dd73-b45e-48b2-8cc2-7df453403608">Humacyte, Inc.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTAtMS0xLTM1MjM0_fe163e8c-4c0c-4eeb-9777-06c5466fc27d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTEtMS0xLTM1MjM0_9b945333-388f-455b-836f-cac9f25257d5">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTItMS0xLTM1MjM0_bcd4d95a-8cab-476b-90f6-ec8230de54cc">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18wLTAtMS0xLTM1MjM0_ffb5f77b-bd9d-4560-a536-982515aef44b">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTAtMS0xLTM1MjM0_e1956b29-1281-4c43-ac73-c209de7e5f2e">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTEtMS0xLTM1MjM0_04ecc258-666e-41b3-abe7-693305a100e1">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTItMS0xLTM1MjM0_1f762db2-44de-44cd-950a-547f17d98974">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8zMjQ_8859d2ba-8dcb-46b2-843e-9023d02db709">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIz_fc1cca00-519b-4433-8987-a270352b2834">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8wLTAtMS0xLTM1MjM0_5b9c4b10-87df-4815-97fb-40c811fd27b6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8xLTAtMS0xLTM1MjM0_1a79717f-17b9-4ecf-8610-a59fd8403556">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8yLTAtMS0xLTM1MjM0_b7cec9ef-7089-4c9a-b886-425d7287d95b">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8zLTAtMS0xLTM1MjM0_2f9119d6-7dbf-43df-a7a3-1f2da0e59bdf">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTAtMS0xLTM1MjM0_6b9f8893-3494-4bf6-88a4-0cbb122919fc">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTItMS0xLTM1MjM0_11a4830d-92bf-4f5c-a8c1-a004e5f72a33">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTQtMS0xLTM1MjM0_c04cfd57-df59-4b60-9e4a-3375c7e19e3f">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTAtMS0xLTM1MjM0_1aea51af-0d70-4a47-becc-6d2a333eb370">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTItMS0xLTM1MjM0_ba85e80f-886c-4b4b-aa16-831a533c37b7">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTQtMS0xLTM1MjM0_14f07edb-e8d6-4d6a-9833-bb244a576899">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE3_9d5b45e5-2a0a-46e9-9fb9-75a8c250c3e4">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE4_db62c0cb-6b0e-4ac3-9140-97706e896972">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1e89ae06699a417e87d4667667970318_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i1e89ae06699a417e87d4667667970318_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220513xexx991.htm">Press release, dated May 13, 2022.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1e89ae06699a417e87d4667667970318_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 13, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20220513xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifbdafff9dde34ddb8f4adea63d3893e9_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="image.jpg" src="image.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:210px"></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2022 Financial Results and Business Update</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Human Acellular Vessels&#8482; (HAVs&#8482;) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries &#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer &#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">  -- </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data &#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Conference call and live webcast at 8&#58;00 a.m. ET today &#8211;</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DURHAM, N.C. &#8211; May 13, 2022 &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the first quarter ended March&#160;31, 2022, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We are pleased by the progress Humacyte has made in the first quarter of 2022 as we continue to advance our universally implantable, bioengineered human tissue platform. We believe our lead candidate, the HAV, is uniquely suited for scenarios in which the current standard of care is unavailable or inadequate. During the humanitarian crisis in Ukraine, we are proud to be able to provide HAVs to front-line hospitals for the treatment of military and civilian vascular trauma injuries.&#8221; said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. &#8220;In addition, we were pleased to welcome Dr. Shamik Parikh as our Chief Medical Officer. Dr. Parikh joins us at a pivotal time, as we look forward to the planned completion of our late-stage clinical trials in vascular trauma and arteriovenous access for hemodialysis and if approved, work to bring the HAV to market in its initial indications.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2022 and Recent Corporate Highlights</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">This week, Humacyte launched an initiative to provide its HAVs to multiple hospitals in Ukraine for the treatment of wounded civilians and soldiers suffering from vascular trauma injuries. The Company worked with the Office of International Programs within the U.S. Food and Drug Administration (FDA), as well as the Ukraine Ministry of Health, to coordinate export and import of the investigational HAV for humanitarian use. Six hospitals in Ukraine, including those located in Kyiv, Kharkiv, and in other cities, will be the recipients of the initial shipment, with additional site requests from Ukraine currently being processed. The Company has also collaborated with surgeons who have extensive experience with the HAV to provide training on the use of the HAV to surgeons in Ukraine. While outside of the scope of the ongoing Phase 2&#47;3 trial in vascular trauma, the Company expects that this humanitarian program will provide additional real-world evidence of the potential impact of the HAV in the treatment of vascular injury.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Humacyte plans to share new HAV clinical immunogenicity data, reporting on bloodwork from patients who have received the HAV, during a presentation at the American Transplant Congress 2022 meeting taking place in Boston June 4-8, 2022. The presentation will be delivered during the &#8216;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bioengineering in Transplantation&#58; Where We are and Where are We Going&#63;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217; session on June 8 at 7&#58;00 a.m. ET.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Humacyte continues to partner with Frenova, a subsidiary of Fresenius Medical Care, a major shareholder and collaborator of the Company, on quantifying the costs of dialysis access in hemodialysis patients in the United States and in Europe. The Company believes that evaluation of rates of infectious and other access complications will enable it to quantify the potential health economic benefits of the HAV in patients with kidney failure.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Throughout the first quarter, the HAV was the subject of multiple presentations at scientific conferences and publications in scientific journals, including&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Results from a case study of a patient who received the HAV as a replacement for an infected synthetic iliofemoral bypass graft were published in the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Vascular Surgery&#58; Cases, Innovations and Techniques</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At 22 months post-implantation, the patient had resumed regular physical activity and no signs of infection of the HAV implant have been observed.</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Surgeons from the Uniformed Services University and Walter Reed National Medical Center of the Health Sciences reported on the first eight FDA-approved expanded access cases using the HAV for arterial repair and reconstruction.  In this case series of patients with either critical limb ischemia or vascular trauma, the HAV was observed to resist infection, provided reliable patency, and offered surgeons an immediately available biologic conduit option.  The report on this case series was published in the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annals of Vascular Surgery </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in April 2022.   </font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Five-year data from a Phase 2 clinical trial of patients receiving the HAV for arteriovenous access in hemodialysis were published in the journal </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EJVES Vascular Forum</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Results showed long-term durability and usability of the HAV during the five-year follow-up period, with no reports of infection or immunogenicity.</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The first preclinical study of the use of the Company&#8217;s small-diameter (3.5 mm) HAV in coronary artery bypass grafting was presented at Advanced Therapies Week. The HAV was observed to maintain patency and exhibited host-cell remodeling and regeneration in a non-human primate (baboon) model, which is considered to be highly predictive of human outcomes.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April, Humacyte announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh leads the Company&#8217;s global clinical development strategy, including oversight of the preclinical and clinical development, clinical operations, and medical affairs functions. Dr. Parikh brings more than two decades of leadership experience in academia and at global pharmaceutical companies, where he oversaw clinical and drug strategy, clinical research and development, product launches, medical affairs and drug safety, across multiple therapeutic areas including a 16-year tenure at AstraZeneca.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2022 Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash, cash equivalents and short-term investments of $206.2 million as of March&#160;31, 2022, compared to $225.5 million as of December&#160;31, 2021. The $19.3 million net use of cash, cash equivalents and short-term investments for the first quarter 2022 resulted from spending related to net operating activities for the quarter, including clinical and earlier-stage programs and preparation for the Company&#8217;s anticipated commercial launch. The Company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the Company&#8217;s current expected timelines for potential approvals of the HAV in vascular trauma and AV access for hemodialysis.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue was $233 thousand for the first quarter of 2022, compared to $155 thousand for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of 2021. Revenue in both periods related to grants supporting the development of the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $16.3 million for the first quarter of 2022, compared to $15.1 million for the first quarter of 2021. The current-period increase resulted primarily from increased personnel and materials expenses designed to support expanded research and development initiatives and the support of clinical trials.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $5.7 million for the first quarter of 2022, compared to $4.8 million for the first quarter of 2021. The current-period increase resulted primarily from the transition to being a public company and preparation for the planned U.S. commercial launch of the HAV, if approved, including increased personnel costs, professional fees and insurance costs.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expenses) was $1.9 million for the first quarter of 2022, compared to $(0.5) million for the first quarter of 2021. The current-period increase in other net income resulted primarily from non-cash gains related to the remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp., partially offset by an increase in interest expense related to the Company&#8217;s loan facility with Silicon Valley Bank.  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $19.8 million for the first quarter of 2022, compared to $20.3 million for the first quarter of 2021. The current-period decrease in net loss resulted from the increase in other net income described above, partially offset by expense increases also described above.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Date&#58;</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Friday, May 13, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; 1-201-389-0920<br>Conference ID&#58; 13729522</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. The HAV is an investigational product and has not been approved for sale by the FDA or any international regulatory agency. For more information, visit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.Humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s cash runway, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; our rights and obligations under our partnership with Fresenius Medical Care&#59; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; our expectations regarding our initiative to provide HAVs to Ukraine&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the impact of COVID-19 on Humacyte&#8217;s business, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, filed by Humacyte with the SEC and in subsequent SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">###</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Heather Anderson</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">6 Degrees</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">919-827-5539</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">handerson&#64;6degreespr.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ifbdafff9dde34ddb8f4adea63d3893e9_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Revenue</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,314&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,682&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,996&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,924&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21,763)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,769)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expenses), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses (net)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,327)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expenses), net </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,832)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,301)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.46)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,004,088&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,874,700&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="ifbdafff9dde34ddb8f4adea63d3893e9_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,222&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,295&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,340&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,540&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264,468</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,037&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,763&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,402&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160,578</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,295&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,405)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,573)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,890&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264,468</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20220513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3b922dbf-dea4-4759-b5c2-38dd01002567,g:a24aa320-4436-4438-b9f7-72b0296329e1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20220513" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20220513">
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220513_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20220513_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3b922dbf-dea4-4759-b5c2-38dd01002567,g:a24aa320-4436-4438-b9f7-72b0296329e1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20220513.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended" id="i827d3dd79de149f7b90b15eb62c30d47_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4b20c5d2-55bd-4db5-a4d3-2e2aae16edaf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_DocumentType_4b20c5d2-55bd-4db5-a4d3-2e2aae16edaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_deced02f-992e-42d7-877c-710fd5ba8d71" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_DocumentPeriodEndDate_deced02f-992e-42d7-877c-710fd5ba8d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_42ac711e-ed67-4600-ab89-95fbd430b67f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityRegistrantName_42ac711e-ed67-4600-ab89-95fbd430b67f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bcd393c5-ff99-4fa6-89e3-74c727694c1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bcd393c5-ff99-4fa6-89e3-74c727694c1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0dba718-d924-4147-833f-cdc575746839" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityFileNumber_f0dba718-d924-4147-833f-cdc575746839" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6786083e-c944-46a8-b678-9dc8334b394d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityTaxIdentificationNumber_6786083e-c944-46a8-b678-9dc8334b394d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_37388ea3-1105-4051-a400-ac61ef7bc913" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressAddressLine1_37388ea3-1105-4051-a400-ac61ef7bc913" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26e4a78a-1c2e-496b-b6fa-2c3edd5a8a4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressCityOrTown_26e4a78a-1c2e-496b-b6fa-2c3edd5a8a4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_95f98c90-0536-42f0-ba8d-c0a0121faefb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressStateOrProvince_95f98c90-0536-42f0-ba8d-c0a0121faefb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_41ac118f-4ed6-46b2-a0b5-9b7034661ccd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressPostalZipCode_41ac118f-4ed6-46b2-a0b5-9b7034661ccd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d96dcce4-b420-449e-95bc-863308f94ab4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_CityAreaCode_d96dcce4-b420-449e-95bc-863308f94ab4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_76721103-5bbf-4939-a46d-9368bebe6091" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_LocalPhoneNumber_76721103-5bbf-4939-a46d-9368bebe6091" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a3bc8d83-ee0c-4b01-83b1-117858a7cde5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_WrittenCommunications_a3bc8d83-ee0c-4b01-83b1-117858a7cde5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_bb418486-6b51-4fa0-b99c-b3f506907d22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_SolicitingMaterial_bb418486-6b51-4fa0-b99c-b3f506907d22" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b534ac55-2d13-4afe-a804-b02c934ca47b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_PreCommencementTenderOffer_b534ac55-2d13-4afe-a804-b02c934ca47b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4d61a9b2-78cc-4e0a-bee5-a56902b7415f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4d61a9b2-78cc-4e0a-bee5-a56902b7415f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37691f42-4262-4dac-b348-5a385950b5ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_Security12bTitle_37691f42-4262-4dac-b348-5a385950b5ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_564ab1ad-3bc2-445f-8159-47eb3c99a604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_TradingSymbol_564ab1ad-3bc2-445f-8159-47eb3c99a604" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_12d340c9-e08e-48ff-a754-801207c37d19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_SecurityExchangeName_12d340c9-e08e-48ff-a754-801207c37d19" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ae11987c-846f-4b6b-bcf3-4b171f02e44a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityEmergingGrowthCompany_ae11987c-846f-4b6b-bcf3-4b171f02e44a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e3c7e6c9-9ac9-49d8-9278-5c0b291f0065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityExTransitionPeriod_e3c7e6c9-9ac9-49d8-9278-5c0b291f0065" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d47bff76-e0a0-441f-bd7d-36968f9c5715" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityCentralIndexKey_d47bff76-e0a0-441f-bd7d-36968f9c5715" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_630d417a-1f0d-4653-b42c-ed331749195a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_AmendmentFlag_630d417a-1f0d-4653-b42c-ed331749195a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8372f6f1-f72b-4792-b937-27c9f25df3cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:to="loc_us-gaap_ClassOfStockDomain_8372f6f1-f72b-4792-b937-27c9f25df3cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:to="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48002468-28fe-4bdd-a10e-2d1141329e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:to="loc_us-gaap_CommonStockMember_48002468-28fe-4bdd-a10e-2d1141329e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_42fc5643-7bae-4a3e-95a2-8c74b49a3dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:to="loc_us-gaap_WarrantMember_42fc5643-7bae-4a3e-95a2-8c74b49a3dba" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20220513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3b922dbf-dea4-4759-b5c2-38dd01002567,g:a24aa320-4436-4438-b9f7-72b0296329e1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressStateOrProvince_6b7a751b-026a-4057-a899-7edcdde639f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_cdb5670b-3044-44ca-8d09-8cab994d863d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0aabbf84-1c8e-4ef0-b964-7e08ae6dc4b2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0edc1011-8d66-4e9e-8800-bce11dfc5a7b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c9ad02a4-0b37-438d-a280-9d6e0848ba18_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b3ad8695-383a-4954-9e71-8cd4abaacfa8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ff4e890f-e337-4a4d-88d5-1e72d94c285b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_fc6048f5-e6b4-47b8-99d0-252db1076000_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_97f58e67-3c70-4bf5-8c2b-a0b7d8f9a7ee_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba336972-9a8b-4eea-99d9-f4243dac4cd8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4a2429ae-4e07-4754-9b9a-60a096c32530_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_21919974-9580-45fb-b726-abe8652e571c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8f0adc97-ab11-44e9-92ce-b0cdae8d8b00_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2c72efd7-d023-4359-a50c-8677f7165e03_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_25f38050-ad6a-4b5d-a964-e574e99c396e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3884563d-271f-436f-b849-65255ab32708_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1c5567c8-2ed6-4e37-bed5-b83f8c5eacdf_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f9c3a21d-82b1-4b51-a5d2-1eb8059a3d7a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b257382b-7cf1-4aca-a203-0bb8c3ea026b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_33c09eee-3026-4685-85b6-6b5acb91cb4e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2429feec-349e-4777-9489-df95cd397994_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dce2083b-f53f-4de0-8890-b860f16878ab_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_40960e0a-2507-47be-b005-073a06265cc9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_18c03708-46cd-4073-85c6-af0dc87a2be8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0c2be50b-63d4-4503-9c80-8252506aa506_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4cee773c-fa45-4b0e-ad60-0778d0a8ef3a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_06dd53af-2ddf-4a68-83af-d3b80b35f460_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_69dbcfc1-39dc-4f69-9f36-210ed12d9be6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_341ed7b0-83c7-4b3e-9314-4aac18efe042_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20220513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3b922dbf-dea4-4759-b5c2-38dd01002567,g:a24aa320-4436-4438-b9f7-72b0296329e1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20220513.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_096a81c5-5531-42e4-bc4c-16a850b4b176" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_096a81c5-5531-42e4-bc4c-16a850b4b176" xlink:to="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8372f6f1-f72b-4792-b937-27c9f25df3cf" xlink:to="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48002468-28fe-4bdd-a10e-2d1141329e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:to="loc_us-gaap_CommonStockMember_48002468-28fe-4bdd-a10e-2d1141329e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_42fc5643-7bae-4a3e-95a2-8c74b49a3dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dd0be5d-1f7a-4f4d-8bf0-1b7b3af9897e" xlink:to="loc_us-gaap_WarrantMember_42fc5643-7bae-4a3e-95a2-8c74b49a3dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ae2010d2-2a0d-48d9-84b6-61d266b5ef8f" xlink:to="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4b20c5d2-55bd-4db5-a4d3-2e2aae16edaf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_DocumentType_4b20c5d2-55bd-4db5-a4d3-2e2aae16edaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_deced02f-992e-42d7-877c-710fd5ba8d71" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_DocumentPeriodEndDate_deced02f-992e-42d7-877c-710fd5ba8d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_42ac711e-ed67-4600-ab89-95fbd430b67f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityRegistrantName_42ac711e-ed67-4600-ab89-95fbd430b67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bcd393c5-ff99-4fa6-89e3-74c727694c1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bcd393c5-ff99-4fa6-89e3-74c727694c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0dba718-d924-4147-833f-cdc575746839" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityFileNumber_f0dba718-d924-4147-833f-cdc575746839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6786083e-c944-46a8-b678-9dc8334b394d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityTaxIdentificationNumber_6786083e-c944-46a8-b678-9dc8334b394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_37388ea3-1105-4051-a400-ac61ef7bc913" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressAddressLine1_37388ea3-1105-4051-a400-ac61ef7bc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26e4a78a-1c2e-496b-b6fa-2c3edd5a8a4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressCityOrTown_26e4a78a-1c2e-496b-b6fa-2c3edd5a8a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_95f98c90-0536-42f0-ba8d-c0a0121faefb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressStateOrProvince_95f98c90-0536-42f0-ba8d-c0a0121faefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_41ac118f-4ed6-46b2-a0b5-9b7034661ccd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityAddressPostalZipCode_41ac118f-4ed6-46b2-a0b5-9b7034661ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d96dcce4-b420-449e-95bc-863308f94ab4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_CityAreaCode_d96dcce4-b420-449e-95bc-863308f94ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_76721103-5bbf-4939-a46d-9368bebe6091" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_LocalPhoneNumber_76721103-5bbf-4939-a46d-9368bebe6091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a3bc8d83-ee0c-4b01-83b1-117858a7cde5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_WrittenCommunications_a3bc8d83-ee0c-4b01-83b1-117858a7cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_bb418486-6b51-4fa0-b99c-b3f506907d22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_SolicitingMaterial_bb418486-6b51-4fa0-b99c-b3f506907d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b534ac55-2d13-4afe-a804-b02c934ca47b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_PreCommencementTenderOffer_b534ac55-2d13-4afe-a804-b02c934ca47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4d61a9b2-78cc-4e0a-bee5-a56902b7415f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4d61a9b2-78cc-4e0a-bee5-a56902b7415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37691f42-4262-4dac-b348-5a385950b5ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_Security12bTitle_37691f42-4262-4dac-b348-5a385950b5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_564ab1ad-3bc2-445f-8159-47eb3c99a604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_TradingSymbol_564ab1ad-3bc2-445f-8159-47eb3c99a604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_12d340c9-e08e-48ff-a754-801207c37d19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_SecurityExchangeName_12d340c9-e08e-48ff-a754-801207c37d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ae11987c-846f-4b6b-bcf3-4b171f02e44a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityEmergingGrowthCompany_ae11987c-846f-4b6b-bcf3-4b171f02e44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e3c7e6c9-9ac9-49d8-9278-5c0b291f0065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityExTransitionPeriod_e3c7e6c9-9ac9-49d8-9278-5c0b291f0065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d47bff76-e0a0-441f-bd7d-36968f9c5715" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_EntityCentralIndexKey_d47bff76-e0a0-441f-bd7d-36968f9c5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_630d417a-1f0d-4653-b42c-ed331749195a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ae9669f2-d5aa-49ff-b28b-e2b118ee855a" xlink:to="loc_dei_AmendmentFlag_630d417a-1f0d-4653-b42c-ed331749195a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
MB5!.1PT*&@H    -24A$4@   6    !4" 8   '+^MW5     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %Q$  !<1 <HF\S\  )M\241!
M5'A>[;T%@%9'LOZ=>_?N7=]LA. ^@X6$N+OC<7=W=W<G0(A[0B"!"(1 $DB"
MN[N[C#"##N/R?/7K\];,F3<SV-K=_Y>:J;?[M'=U=76UG#Z[* E*#<N"K<0L
M9N/!'0,6VP]09MZ$,6NIV0E4'@;_TL@MN)M#^(_<@K>#AP^.27Y5P"\*K+)$
MQE86LI.L@/8<)13Y!3L_P8(_R(/')2:5*0EI1.DDP./%L,PJG!2J6B@O<%F@
M AE@2@66:;'EJ<(MVC)FN"9=?[W>JE=/+]?872_M\2=U:=I$'[<]29]>>8$&
MW'>W?GCR:0U[X7G]^-23^O;>^]7GNBOTV;EGZ\.33M4[QQROT;??KC6]>ZMX
MT4)IRV85%Y:HI$C*+\JW^B4JFBATL%8#5F"+92&*2HM54E)F6*J<_OTTI4D+
MS6VXIP8W;ZA5O;\P0EK"%@%T*#/*TL0A&\^%![-# "J/<P5:(1-N44J%TJ8"
MS>TW0#]]\HE63)HLY16HI-C<8;/0:I5A%V(;+5546*;E]SZDK.9UM+1E34UL
M>X)%S N)%U.G*B)O#;8W/-V@U-BPQ,)O*<RW5C4BE)IC,6X)BIN?I[>+\#28
MUJZ#LIK54E9J XUK7%=%QI;%D,MJNGSELA"&2&W;M@WV-]]\,YAWW'%',->O
M7Z]2FC8)LK.SK=6B/##OO?=>G7O^>>H_X!NMV[!>:]+7A (.^?''4,#3.K13
MN],[JD/'#B%.ITZ= G[__??A>9>0A?U,//%D93>KK_4IC;0BI;8*<O-58(6F
M$9<M6AH" VW:M GF<\\]%\R++KHHF(<??KB*BZV*5NA##CDDN $M6[;4S)DS
M@_V<<\X)_E1\^O3IP6RS[_XJ,E;<?[_]PS-LM/^!!QAU0A0-'CPXF!44Y@%:
M4O*IT[3P^FLTJF5#36AFE+[A)BFW2'/GS]?HT:,U?/APU:I5BRAZ^.&'0R+M
MV[</SWONN:<:-6JDO??>6W/GS@UN0/_^_?6G/_TI5&:WW78KS]@!]P<>>"#Q
M%!6,M!RNO?9:/?_\\XFG! \#-%HDA"R2/>19APJ2PIIISIPY@3(TZ?_^[_^&
M,*><<DK(K$F3)N'Y][__??#?O'FS9LR8$=R..^XXW6[2 >H#9Y]]MHJ*BD):
M'W_\<3!!*N1 &K_][6\33](WWWP33,(!NU!0RDQC),H;(-3#?LI,BDR?-CMR
ML]K_^<]_#HE^^.&'VF67731V[-B0V%__^M?@#GB!CSSRR'**[K'''L%^\\TW
MAWBT%L_$)4V'Y&?B@9T[=P[/OQPX_H_#+PH<T0A!5U!!<:A43O*(8I$GK<(S
M$C8:$<-S"$+W281)1(FZ5/EC\"IW"([E/M7"+RF,[$LD%'C:"EB>GOUZ$P>'
M(!)!"P<[X,>P3'PJ8!9^$Y$C?^P)#'Y "+]]4+G UM%(A+R+C%+%)HS+TE=H
MW:L]],DA!ZN;]?(7=_^C7JI=0V\<?(!ZGME!O:^_4H,>>5B#'GU2/S[]E+Y_
MZ&%]?>L=^N+*2_19Q\YZ]]B3-."\\[3TM1[*'S].RMF@LMQ<&ZBL,J5%AD:6
M4'%*O>V2AP*7,"Q;X4*?L7%^O$F A4UJ:4:C&AIVR85&BB(C2():!A&A^&-H
MC@@6_21,0Q^":9&H46@O"Q_L_-CP:T-PZ=R%&M'];<WY>9AR5JQ2F8UV9=;Q
MRELR"2*Q9G*LK#!7,QK65WIJ7<UI7E-:O59%!;DFNF)L\ ^ 2BG!/;2D4;C
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MH6G.!3UMTVF.ZG( "B*RO>25^/333\M/T"('J7#050TNO/#"\A-?\4K'[3
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M9&O@_JA1J$[0:UL,3)M <SJCORV$+@\B?%@58B1CE(N7N2K8Q4IOI:""AHG
M_.(2BL8#[F6FQQJ;VK3,G-"2HYEK\"<@$M32BHX@(A5@U&C=EWLL\^V/Z[_R
M28.M4[9)PWIOE 2WBP!SYLS3G_[PYW#$/_D=#P=_?NJIIT(X>BSWJ@'X07B&
M,XB)M'SVV6?+7\\%:# DIG< F(VT $\;!D8B0.CXU6#.,#0P4M#S<Z C(86X
MGBS.P""O,,"<O%V%A$8*PS"\G82=>+AC\KX*^C2W"@)>+AB-H9?TZ02L=,1?
MGP H#YV#E0HZ,HS)*@MAG)D=/%V6JZ EY?-[O[VN'J8J<#]HP>MOE,M5I^H
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MXYJ:7K^6QM2KK0DV:Y]SPS4V _]8N0MFFO0P'2W13F76.<I,NH3S#>4-\H\
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M&=\KGYR.N\7#.7@<1T]O1\#S<_2TD@$W_/U5=^S; YY>2!MZX6;HRW^^/ =
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MZ7Q;8V#:C7+[/ #:LY%#_3'9X(F;K,AL#1*OU=,(4<.5,ZYC',(SX8B#61'
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MR;+'K6 %$#::$%<4(H&>?O G4@))@+7]F%/T[!AS_V6&!E 6^OHDW*?[[!2
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M:&:"5SU$,CH[5^6/6_1;#5:B$?F6^P0LAU\X1(_$"GW&(C(KBTII&,)&SSZ
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M^27,GS\_?'3\P@LO# /1\.'#RP< @#+$A:D+G3CP[&&P5Q4'P8@=0.-E $)
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M60&,YLK^"NF0GO<[GD$T>]J(=L8?'L&$OW$'&7S^YW_^)_ L_,JFK;\ ]?=
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M"-/[U)UGEA?0B-FMYTT?ILRD18=U[2&."$R6/3A#RT804RG2<&'AZ8+)]7!
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I7^%7^#?!KP+X5_@5?H5?X=\"TO\'GVM_Z3P1[XL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139634378986472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 13, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20220513_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20220513.xsd" xlink:type="simple"/>
    <context id="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF80L2ZyYWc6ZmE0Njk0OTg0OGQyNDgzYzhkMzBmOWVmYjBhYjIwYTgvdGFibGU6ZjdjODc3MDk1ZjdhNDAxMzhmZGQwNWJiZmJjYmE4NzYvdGFibGVyYW5nZTpmN2M4NzcwOTVmN2E0MDEzOGZkZDA1YmJmYmNiYTg3Nl8xLTEtMS0xLTM1MjM0_a56adc0c-46e9-45ab-ba2f-7235f7249cd1">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF80L2ZyYWc6ZmE0Njk0OTg0OGQyNDgzYzhkMzBmOWVmYjBhYjIwYTgvdGFibGU6ZjdjODc3MDk1ZjdhNDAxMzhmZGQwNWJiZmJjYmE4NzYvdGFibGVyYW5nZTpmN2M4NzcwOTVmN2E0MDEzOGZkZDA1YmJmYmNiYTg3Nl8yLTEtMS0xLTM1MjM0_2d2c3adf-ddff-471e-80ca-7d337d2598eb">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE5_44d2f2e5-d581-4207-a82a-6369bf73b831">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIw_4c30aa86-e978-4217-88ae-5839d6c0729f">2022-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIx_77eb2a80-d35d-4625-b958-715baf3fc9cf">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIy_3c90dd73-b45e-48b2-8cc2-7df453403608">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTAtMS0xLTM1MjM0_fe163e8c-4c0c-4eeb-9777-06c5466fc27d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTEtMS0xLTM1MjM0_9b945333-388f-455b-836f-cac9f25257d5">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZjUwMjkwZWNmODM4NDdlM2FkNThmMmFlYjRlMTA4YTUvdGFibGVyYW5nZTpmNTAyOTBlY2Y4Mzg0N2UzYWQ1OGYyYWViNGUxMDhhNV8wLTItMS0xLTM1MjM0_bcd4d95a-8cab-476b-90f6-ec8230de54cc">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18wLTAtMS0xLTM1MjM0_ffb5f77b-bd9d-4560-a536-982515aef44b">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTAtMS0xLTM1MjM0_e1956b29-1281-4c43-ac73-c209de7e5f2e">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTEtMS0xLTM1MjM0_04ecc258-666e-41b3-abe7-693305a100e1">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGFiNjY4ZDdjMTY1NGNjMjgyMGI5OGMxOTYwNGVmNTcvdGFibGVyYW5nZTpkYWI2NjhkN2MxNjU0Y2MyODIwYjk4YzE5NjA0ZWY1N18xLTItMS0xLTM1MjM0_1f762db2-44de-44cd-950a-547f17d98974">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8zMjQ_8859d2ba-8dcb-46b2-843e-9023d02db709">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjIz_fc1cca00-519b-4433-8987-a270352b2834">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8wLTAtMS0xLTM1MjM0_5b9c4b10-87df-4815-97fb-40c811fd27b6">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8xLTAtMS0xLTM1MjM0_1a79717f-17b9-4ecf-8610-a59fd8403556">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8yLTAtMS0xLTM1MjM0_b7cec9ef-7089-4c9a-b886-425d7287d95b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6ZGY0Y2QxYjlhNjYwNGU3YjllYWM5NWU0YjkxZmUwN2IvdGFibGVyYW5nZTpkZjRjZDFiOWE2NjA0ZTdiOWVhYzk1ZTRiOTFmZTA3Yl8zLTAtMS0xLTM1MjM0_2f9119d6-7dbf-43df-a7a3-1f2da0e59bdf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTAtMS0xLTM1MjM0_6b9f8893-3494-4bf6-88a4-0cbb122919fc">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTItMS0xLTM1MjM0_11a4830d-92bf-4f5c-a8c1-a004e5f72a33">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibc523c4f49b4420ea0580c04cceed37a_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18xLTQtMS0xLTM1MjM0_c04cfd57-df59-4b60-9e4a-3375c7e19e3f">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTAtMS0xLTM1MjM0_1aea51af-0d70-4a47-becc-6d2a333eb370">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTItMS0xLTM1MjM0_ba85e80f-886c-4b4b-aa16-831a533c37b7">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i09b41272cd5a467d861363d163bb36fc_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGFibGU6MzNjNzYwYjZmOGQyNGJmZWFjM2FjMjI0MTJiY2EzMzcvdGFibGVyYW5nZTozM2M3NjBiNmY4ZDI0YmZlYWMzYWMyMjQxMmJjYTMzN18yLTQtMS0xLTM1MjM0_14f07edb-e8d6-4d6a-9833-bb244a576899">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE3_9d5b45e5-2a0a-46e9-9fb9-75a8c250c3e4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlODlhZTA2Njk5YTQxN2U4N2Q0NjY3NjY3OTcwMzE4L3NlYzoxZTg5YWUwNjY5OWE0MTdlODdkNDY2NzY2Nzk3MDMxOF8xL2ZyYWc6MmVmNGQ5NzVmNTYxNGU3M2I4M2FlNDBhMDk1Y2QyY2IvdGV4dHJlZ2lvbjoyZWY0ZDk3NWY1NjE0ZTczYjgzYWU0MGEwOTVjZDJjYl8xMjE4_db62c0cb-6b0e-4ac3-9140-97706e896972">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MS9A=;^(X%(:O9W^%A>9B5Z)-XI0"(XI$:3M%,^VPI;.5=K47)C'$:A)G;:?
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !P.*U4F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M ' XK506)WAAX00  .P4   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !P.*U4GZ ;\+$"  #B#   #0
M            @ $D#0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ' XK527
MBKL<P    !,"   +              "  0 0  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ' XK509117U-P$  "<"   /              "  >D0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !P.*U4)!Z;HJT   #X 0  &@
M        @ %-$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !P.*U499!YDAD!  #/ P  $P              @ $R$P  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !\%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20220513.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20220513.htm">huma-20220513.htm</File>
    <File>huma-20220513.xsd</File>
    <File>huma-20220513_def.xml</File>
    <File>huma-20220513_lab.xml</File>
    <File>huma-20220513_pre.xml</File>
    <File>huma-20220513xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20220513.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20220513_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20220513.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20220513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20220513_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20220513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20220513",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20220513.htm",
      "contextRef": "i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20220513.htm",
      "contextRef": "i196154cc97c3493bbdabe1c634f229e9_D20220513-20220513",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-22-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-22-000037-xbrl.zip
M4$L#!!0    ( ' XK504U!2^>!8  "N>   1    :'5M82TR,#(R,#4Q,RYH
M=&WM/?M7XDC6O^]?41^SWZY]C@5Y/^AN]]B"#C,"W8KMP"]]*E45$PR$28*
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M$ [21"]YI?1(J05&4SR,5J'1ZUNSFV*X*G<;KB4G9!/XXR6]8.^_4$L#!!0
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MM1<N66/U0^M>__\Q<.L U?\P!/Z.HW\$^FJY[#8+HZ#W?0HTEX92+I4AW"3
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M>R)OECK.P5FJ>:X5N(WR*_!5Z>P["--D";XFZ??H!X?P=?FBL^3Z/HTNKW*
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MT(L\VSQ39@*(G/7.F5^:1Q@E'>P,;I,-=AO9U^RSXOY8JOE9HO2<!:%'M1]
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M7*G"W1\+?CG'7D@H\A#DJCAJ*#P%>7&4P+1P9H+')&%^YYLS6YZG)O '<*!
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M<EVM9I^J^G/QQ0&\["_:KTXOZ^+XI)TQPMC=3^MGW%O&HL\0DQ,@M+3@96#
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MR"\DW#(W#(5MZ8H^7LG)$'@^OZ<DSNOSRR?7'W2'[BOR+Y_\'U!+ P04
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M_0;,X7OA=JTPS3R-^]R^&89^XCD53>X!_??Z\<1OK$3\GY,QMZ>Q8(;RF^6
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M.TD*:0A:';+7LEMX'QR?)%Y\RZIG3=OFH'I1=H7Z<Q2:R01\*"I]P)@W%3Z
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MTJH\!#I(4P<#BM3'8: [W8#%5<#(]!JS<L\'6E&+4%\!.1%+8B5MO:T<K%I
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MF-6)3:O6?>#[($J$EPY^D\Z:Z^9]E ]>E#\A6!62;DPK'&+A7J/6LQJ]==_
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M+1_(._A-JO?6/5';;U14AH3 S:B&0TP=J]?P/:EES!P[)@4^<F?K5JU=YIS
M^1.)]3I6[ZZXNOPS?!;1:7^%%SH^#]\)_K1::U<Q'EW<)]^FIM79923B (\I
MBRG]7GK42LNEE$N_#]/BV$).O5$,WP:K<6'@A_C]?2_..5!7I&:US]9]1]?1
M87SZ3-EZ[>@Q/D%M^M>?F.MSSQQ\/LM8>:-K=9L[S/@](HD5=ZG9>>#;%8]
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M4$L! A0#%     @ <#BM5!34%+YX%@  *YX  !$              ( !
M &AU;6$M,C R,C U,3,N:'1M4$L! A0#%     @ <#BM5*P(41^: @  !PD
M !$              ( !IQ8  &AU;6$M,C R,C U,3,N>'-D4$L! A0#%
M  @ <#BM5%O5/3^R"   4#X  !4              ( !<!D  &AU;6$M,C R
M,C U,3-?9&5F+GAM;%!+ 0(4 Q0    ( ' XK51>D#AM10T  &EX   5
M          "  54B  !H=6UA+3(P,C(P-3$S7VQA8BYX;6Q02P$"% ,4
M" !P.*U4D3$:R#@(  #P0   %0              @ '-+P  :'5M82TR,#(R
M,#4Q,U]P<F4N>&UL4$L! A0#%     @ <#BM5-3UON*N(P  -4X! !@
M         ( !.#@  &AU;6$M,C R,C U,3-X97AX.3DQ+FAT;5!+!08
..!@ & (T!   <7      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
